PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number 10537449 Filing Date 2006-01-09 **INFORMATION DISCLOSURE** First Named Inventor Bernd Schwenzer STATEMENT BY APPLICANT Art Unit 1635 (Not for submission under 37 CFR 1.99) Dana H Shin **Examiner Name** Attorney Docket Number 101215-189

U.S.PATENTS						PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	Date	of cited Document Relevan		,Columns,Lines where ant Passages or Relevant s Appear			
/DS/	1	5489508		1996-02	2-06	West et al.		Entire document.			
/DS/	2	5645986		1997-07	'- 08	West et al.		Entire d	ocument.	·	
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	, , , , , , , , , , , , , , , , , , , ,		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
/DS/	1	20020045588	A1	2002-04	I-18	Monia et al.		Entire d	ocument.		
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
				FOREIG	GN PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patented Applicant of cited Document	e or v F	here Rel	or Relevant	T5
/DS/	1	0 666 313	EP		A2	1995-08-09	Univ Iowa Res Fou	nd E	ntire docu	ment.	×
/DS/	2	98 28442	wo			1998-07-02	Geron Corporation	E	intire docu	ment.	X

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10537449
Filing Date		2006-01-09
First Named Inventor	Bernd	Schwenzer
Art Unit		1635
Examiner Name	Dana	H Shin
Attorney Docket Number		101215-189

3	97 37691	wo					
				1997-10-16	Lynx Therapeutics Inc.	Entire document.	X
4	01 88198	wo	A	2001-11-22	Monia Brett P.	Entire document. Cited in International Search Report. Copy of document not provided.	
5	99 50279	wo	A	1999-10-07	Lingner Joachim	Entire document. Cited in International Search Report. Copy of document not provided.	
h to ac	dd additional Foreign Pa	atent Document	citation	information pl	ease click the Add butto	n Add	
		NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
/1	SCHINDLER ASCAN ET AL.; "Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro"; International Journal of Oncology; volume 19, no. 1, July 2001, pages 25-30. Entire document. Cited in International Search Report. Copy of document not provided.						
2							
3	KOGA S ET AL.; "Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA"; Gene Therapy; volume 8, no. 8, April 2001; pages 654-658. Entire document. Cited in International Search Report. Copy of document not provided.						
4	SARTEZKI GABRIELE ET AL.; "Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells"; Cancer Gene Therapy; volume 8, no. 10, October 2001, pages 827-834. Entire document. Cited in International Search Report. Copy of document not provided.						
5	YOKOYAMA YASUHIRO ET AL.; "The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity"; Biochemical and Biophysical Research Communications; volume 273, no. 1, June 24, 2000, pages 316-321. Entire document. Cited in International Search Report. Copy of document not provided.						
6	SCHERR MICHAELA ET AL; "RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts"; Nucleic Acids Research; volume 28, no. 13, July 1, 2000; pages 2455-2461. Entire document. Cited in International Search Report. Copy of document not provided.						
	Cite No /1	Cite No Include name of the a (book, magazine, jour publisher, city and/or or viability of prostate cancentire document. Cited ZHANG Y ET AL.; "Effect Cell Biology International Search Report. Copy of KOGA S ET AL.; "Treatment Therapy; volume 8, no. of document not provided. SARTEZKI GABRIELE 8 telomere shortening in of Entire document. Cited YOKOYAMA YASUHIRO telomerase activity"; Biopages 316-321. Entire of SCHERR MICHAELA Estudies in cell extracts";	h to add additional Foreign Patent Document NON-PATEI Cite No Include name of the author (in CAPIT/ (book, magazine, journal, serial, symp publisher, city and/or country where provided in International Serial in the serial i	NON-PATENT LITI Cite No Include name of the author (in CAPITAL LET (book, magazine, journal, serial, symposium, publisher, city and/or country where publisher (stability of prostate cancer cells in vitro"; Internation Entire document. Cited in International Search Research Report. Copy of document not provided. ZHANG Y ET AL.; "Effect of antisense hTERT mR Cell Biology International; volume 26, no. 5, May 2 Search Report. Copy of document not provided. KOGA S ET AL.; "Treatment of bladder cancer cells and blook telomere shortening in ovarian cancer cells"; Cancel Entire document. Cited in International Search Research; Copy of document. Cited in International Search Research; Scherk MICHAELA ET AL; "RNA accessibility proceeds and coll extracts"; Nucleic Acids Research; Studies in cell extracts"; Nucleic Acids Research; Studies in cell extracts"; Nucleic Acids Research; Studies in cell extracts; Studies in cell extracts; Nucleic Acids Research; Studies in cell extracts; Studies in cell extract	NON-PATENT LITERATURE DO NON-PATENT LITERATURE DO Include name of the author (in CAPITAL LETTERS), title of (book, magazine, journal, serial, symposium, catalog, etc), of publisher, city and/or country where published. SCHINDLER ASCAN ET AL.; "Human telomerase reverse transcr viability of prostate cancer cells in vitro"; International Journal of O Entire document. Cited in International Search Report. Copy of delibility of prostate cancer cells in vitro and in Therapy; volume 2, no. 5, May 2002, pages 427 Search Report. Copy of document not provided. KOGA S ET AL.; "Treatment of bladder cancer cells in vitro and in Therapy; volume 8, no. 8, April 2001; pages 654-658. Entire document not provided. SARTEZKI GABRIELE ET AL.; "Ribozyme-mediated telomerase in telomere shortening in ovarian cancer cells"; Cancer Gene Therap Entire document. Cited in International Search Report. Copy of documents. Cited in International Search Report. Copy of documents and Biophysical Research Commitments and Biophysical Research Commitments and Biophysical Research Commitments and Biophysical Research Commitments in cell extracts"; Nucleic Acids Research; volume 28, no. 1	NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when approp (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-is publisher, city and/or country where published. SCHINDLER ASCAN ET AL.; "Human telomerase reverse transcriptase antisense treatment viability of prostate cancer cells in vitro"; International Journal of Oncology; volume 19, no. 1, Entire document. Cited in International Search Report. Copy of document not provided. ZHANG Y ET AL.; "Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase ac Cell Biology International; volume 26, no. 5, May 2002, pages 427-431. Entire document. Ci Search Report. Copy of document not provided. KOGA S ET AL.; "Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense to Therapy; volume 8, no. 8, April 2001; pages 654-658. Entire document. Cited in International document not provided. SARTEZKI GABRIELE ET AL.; "Ribozyme-mediated telomerase inhibition induces immediate telomere shortening in ovarian cancer cells"; Cancer Gene Therapy; volume 8, no. 10, Octobe Entire document. Cited in International Search Report. Copy of document not provided. YOKOYAMA YASUHIRO ET AL.; "The 5'-end of hTERT mRNA is a good target for hammerh telomerase activity"; Biochemical and Biophysical Research Communications; volume 273, no pages 316-321. Entire document. Cited in International Search Report. Copy of document of SCHERR MICHAELA ET AL.; "RNA accessibility prediction: A theoretical approach is consiste studies in cell extracts"; Nucleic Acids Research; volume 28, no. 13, July 1, 2000; pages 245:	document not provided. 5 99 50279 WO A 1999-10-07 Lingner Joachim Entire document. Cited in International Search Report. Copy of document not provided. NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. SCHINDLER ASCAN ET AL.; "Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro"; International Journal of Oncology; volume 19, no. 1, July 2001, pages 25-30. Entire document. Cited in International Search Report. Copy of document not provided. ZHANG Y ET AL.; "Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells"; Cell Biology International; volume 26, no. 5, May 2002, pages 427-431. Entire document. Cited in International Search Report. Copy of document not provided. KOGA S ET AL.; "Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA"; Gene Therapy; volume 8, no. 8, April 2001; pages 654-658. Entire document. Cited in International Search Report. Copy of document not provided. SARTEZKI GABRIELE ET AL.; "Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells"; Cancer Gene Therapy; volume 8, no. 10, October 2001, pages 827-834. Entire document. Cited in International Search Report. Copy of document not provided. YOKOYAMA YASUHIRO ET AL.; "Ribozyme-mediated Research Communications; volume 273, no. 1, June 24, 2000, pages 316-321. Entire document. Cited in International Search Report. Copy of document not provided. SCHERR MICHAELA ET AL.; "RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts"; Nucleic Acids Research; volume 28, no. 13, July 1, 2000; pages 2455-2461. Entire document.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

			_
Application Number		10537449	
Filing Date		2006-01-09	
First Named Inventor	Berno	d Schwenzer	
Art Unit		1635	
Examiner Name	Dana	a H Shin	
Attorney Docket Number		101215-189	

/DS/	7	PATZEL V ET AL; "A Theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability"; Nucleic Acids Research, Oxford University Press, Surrey, GB; volume 27, no. 22, November 15, 1999, pages 4328-4334. Entire document. Cited in International Search Report. Copy of document not provided.						
/DS/	/DS/ 8 WHITE LAURA K ET AL.; "Telomerase inhibitors"; Trends in Biotechnology; volume 19, no. 3, March 2001, pages 114-120. Entire document. Cited in International Search Report. Copy of document not provided.							
/DS/	9	KRAEMER KAI ET AL; "Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells"; Clinical Cancer Research: An Official Journal of the American Association for Cancer Research; September 1, 2003, volume 9, no. 10, PT 1, pages 3794-3800. Entire document. Cited in International Search Report. Copy of document not provided.						
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner Signature /Dana Shin/ Date Considered 04/26/				04/26/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								